Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2016/3631764 http://scihub22266oqcxt.onion/10.1155/2016/3631764 C4913005!4913005!27366153     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27366153&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Stem+Cells+Int 2016 ; 2016 (ä): ä Nephropedia Template TP {{tp|p=27366153|t=2016. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies |pdf=|usr=}}{{27366153}} gab.com Text Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies JO: Stem Cells Int http://www.kidney.de/pget.php?&tw=1&pmid=27366153 #FOAvip Osteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the outcome for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to explain the resistance of OS to chemotherapy is the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis. These subpopulations of CSCs commonly emerge during tumor evolution from the cell-of-origin, which are the normal cells that acquire the first cancer-promoting mutations to initiate tumor formation. In OS, several cell types along the osteogenic lineage have been proposed as cell-of-origin. Both the cell-of-origin and their derived CSC subpopulations are highly influenced by environmental and epigenetic factors and, therefore, targeting the OS-CSC environment and niche is the rationale for many recently postulated therapies. Likewise, some strategies for targeting CSC-associated signaling pathways have already been tested in both preclinical and clinical settings. This review recapitulates current OS cell-of-origin models, the properties of the OS-CSC and its niche, and potential new therapies able to target OS-CSCs. Twit Text FOAVip Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies ????Stem Cells Int http://www.kidney.de/pget.php?&tw=1&pmid=27366153 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27366153 #FOAvip English Wikipedia <ref>{{Cite pmid|27366153}}</ref> Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies #MMPMID27366153 Abarrategi A; Tornin J; Martinez-Cruzado L; Hamilton A; Martinez-Campos E; Rodrigo JP; González MV; Baldini N; Garcia-Castro J; Rodriguez R Stem Cells Int 2016[]; 2016 (ä): ä PMID27366153show ga Osteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the outcome for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to explain the resistance of OS to chemotherapy is the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis. These subpopulations of CSCs commonly emerge during tumor evolution from the cell-of-origin, which are the normal cells that acquire the first cancer-promoting mutations to initiate tumor formation. In OS, several cell types along the osteogenic lineage have been proposed as cell-of-origin. Both the cell-of-origin and their derived CSC subpopulations are highly influenced by environmental and epigenetic factors and, therefore, targeting the OS-CSC environment and niche is the rationale for many recently postulated therapies. Likewise, some strategies for targeting CSC-associated signaling pathways have already been tested in both preclinical and clinical settings. This review recapitulates current OS cell-of-origin models, the properties of the OS-CSC and its niche, and potential new therapies able to target OS-CSCs. äOsteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapi(epmc).pdf DeepDyve Pubget Overpricing